AstraZeneca has been successful at rolling out its long-acting complement C5 inhibitor Ultomiris in the uses approved for its predecessor Soliris – until now, that is. The drugmaker confirmed this ...
Autolus has picked up its first product approval, getting an FDA green light for Aucatzyl as a treatment for patients with aggressive blood cancer acute lymphoblastic leukaemia (ALL). The US regulator ...
A panel discussion covers considerations within REMS programs aimed at minimizing risks associated with bispecific therapy. NOTE: Not all FDA-approved bispecific antibodies are associated with a REMS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback